Four things to know:
1. NVG-291 is a linear peptide comprised of common amino acids.
2. Its Phase 1 safety and pharmacokinetic study in healthy subjects will begin in the first quarter of 2020.
3. The expansion of its Phase 1 trial on spinal cord injury patients will begin in the second half of 2020.
4. A Phase 2 multiple sclerosis trial is set for the first quarter of 2021.
More articles on biologics:
‘A dream come true’: Dr. Jorge Chahla strives for success at Rush
New York hospital invests $2M in imaging system for spine, brain — 4 things to know
What Stryker’s spine division stands to gain from 5 acquisitions
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
